The IMpassion trials, in contrast, used the SP142 PD-L1 immunohistochemistry assay (Ventana, Tucson, AZ), measuring the proportion of tumor area that is occupied by PD-L1 staining in IC with cut-off in >1% of staining [58, 71, 72]. This evidence concerns the gene CD274 and neoplasm.